JP Morgan Cuts Endo Pharma to 'Long-term Buy'

Analyst Corey Davis says the stock will suffer if the company's cancer pain drug isn't approved

JP Morgan downgraded Endo Pharma (ENDP ) to long term buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.